T-cell therapies for epstein-barr virusassociated lymphomas

Pediatric Hematology and Oncology

Volumn 28, Issue 8, 2011, Pages 627-639

  El Bietar, Javier ^a   Bollard, Catherine ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

HSCT; Immunotherapy; Lymphoma; Lymphoproliferative disorders

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; EPSTEIN BARR VIRUS ANTIGEN 1; IMMUNOSUPPRESSIVE AGENT; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; MESSENGER RNA; METHOTREXATE; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; EPSTEIN BARR VIRUS ASSOCIATED LYMPHOMA; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NATURAL KILLER T CELL; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; REVIEW;

ANTIGENS, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA; T-LYMPHOCYTES;

EID: 80054969329     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2011.628367     Document Type: Review

References (67)

1. Cohen JI. Clinical aspects of Epstein-Barr virus infection. In: Robertson ES, ed. Epstein-Barr Virus. Norfolk, UK: Caister Academic Press; 2005:35-55.
2. Kieff E. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: LippincottWilliams & Wilkins; 2007:2604-2654.
3. Bollard CM, Cooper LJ,Heslop HE. Immunotherapy-targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol. 2008;21:405-420.
4. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. LipincottWilliams & Wilkins; 2007:2655-2700.
5. God JM, Haque A. Burkitt lymphoma: pathogenesis and immune evasion. J Oncol. 2010;2010. pii: 516047. Epub 2010 Oct 5.
6. Khanna R, Burrows SR, Steigerwald-Mullen PM, et al. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. Int Immunol. 1997;9:1537-1543. (Pubitemid 27434686)
7. Heller KN,UpshawJ, Seyoum B, et al.Distinctmemory CD4+T-cell subsetsmediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers. Blood. 2007;109:1138-1146. (Pubitemid 46220661)
8. Kuze T,NakamuraN,Hashimoto Y, et al.The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(F) andEBV(F) cases in Japanese population. Jpn J Cancer Res. 2000;91:1233-1240. (Pubitemid 32042357)
9. Solomides CS,Miller AS, Christman RA, et al. Lymphomas of the oral cavity: histology, immunologic type, and incidence of Epstein-Barr virus infection. Hum Pathol. 2002;33:153-157. (Pubitemid 34298728)
10. Ma L, Katz Y, Sharan KP, et al. Epstein-Barr virus positive anaplastic large cell lymphoma: myth or reality? Int J Clin Exp Pathol. 2010;4:100-110.
11. Herling M, Rassidakis GZ, Jones D, et al. Absence of Epstein-Barr virus in anaplastic large cell lymphoma: a study of 64 cases classified according to World Health Organization criteria. Hum Pathol. 2004;35:455-459. (Pubitemid 38507082)
12. Kuze T, Nakamura N, Hashimoto Y, et al. Clinicopathological, immunological and genetic studies of CD30+ anaplastic large cell lymphoma of B-cell type; association with Epstein-Barr virus in a Japanese population. J Pathol. 1996;180:236-242. (Pubitemid 26393669)
13. Meijer CJ, JiwaNM,Dukers DF, et al. Epstein-Barr virus and human T-cell lymphomas. SeminCancer Biol. 1996;7:191-196. (Pubitemid 26395121)
14. Anagnostopoulos I, HummelM, Stein H. Frequent presence of latent Epstein-Barr virus infection in peripheral T cell lymphomas. A review. Leuk Lymphoma. 1995;19:1-12.
15. Heslop HE. Biology and treatment of Epstein-Barr viurs associated non-Hodgkin's lymphomas. In: Hematology American Society Hematology Education Program 2005:260-266.
16. Metzger M, Krasin MJ, Hudson MM, Onciu M. Hodgkin lymphoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2011:638-662.
17. Brauninger A, Hansman ML, Strickler JG. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med. 1999;340:1239-1247. (Pubitemid 29181644)
18. Pallesen G, Hamilton-Dutoit SJ, et al. Expression of Epstein Barr virus late gene products in tumour cells of Hodgkin's disease. Lancet. 1991;337:320-322.
19. Dunleavy K, Bollard CM. Sobering realities of surviving Hodgkin lymphoma. Blood. 2011;117:1772-1773.
20. Kim JW, Kim BS, Bang SM, et al; on behalf of the Korean Society of Blood andMarrow Transplantation. Allogeneic stem cell transplantation in patientswith non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. Ann Hematol. Epub 2011 Apr 6.
21. Wudhikarn K, Brunstein CG, Bachanova V, et al. Relapse of Lymphoma after Allogeneic hematopoietic cell transplantation: management strategies and outcome. Biol Blood Marrow Transplant. 2011;17:1497-1504.
22. Bloor AJ, Thomson K, Chowdhry N, et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:50-58. (Pubitemid 350286737)
23. Cavattoni I, Zabelina T, Ayuk F, et al. Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation. Leuk Lymphoma. 2010;51:146-148.
24. Peggs KS, Sureda A, Qian W, et al; UK and Spanish Collaborative Groups. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol. 2007;139:70-80. (Pubitemid 47389932)
25. Bollard CM, Gottschalk S, Helen HulsM, et al. Goodmanufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy. 2011;13:518-522.
26. Roskrow MA, Suzuki N, Gan Y, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998;91:2925-2934. (Pubitemid 28227543)
27. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus +Hodgkin's disease. J Exp Med. 2004;200:1623-1633. (Pubitemid 40094186)
28. Cho HI, Hong YS, Lee MA, et al. Adoptive transfer of Epstein-Barr virus-specific cytotoxic Tlymphocytes for the treatment of angiocentric lymphomas. Int J Hematol. 2006;83:66-73. (Pubitemid 43172746)
29. Sun Q, Burton R, Reddy V, et al. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br J Haematol. 2002;118:799-808. (Pubitemid 35007385)
30. Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer. 2004;100:1892-1901. (Pubitemid 38529567)
31. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110:2838-2845. (Pubitemid 350006936)
32. Bollard CM, Dotti G, Gottschalk S, et al. Administration of tumor-specific cytotoxic T lymphocytes engineered to resist TGF-β to patientswith EBV-associated lymphomas. Blood (ASH Annual Meeting Abstracts). 2010;116:560.
33. Fox CP, Haigh TA, Taylor GS, et al. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK-and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood. 2010;116:3695-3704.
34. Heslop HE. How I treat EBV lymphoproliferation [review]. Blood. 2009;114:4002-4008.
35. Swerdlow SH, Webber SA, Chadburn A, Ferry J. Post transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, eds. Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008:342-349.
36. Gottschalk S, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disorders. Annu RevMed. 2005;56:29-44.
37. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: amulti-institutional study. Blood. 1999;94:2208-2216. (Pubitemid 29467666)
38. Kennedy-Nasser AA, Bollard CM, Heslop HE. Immunotherapy for Epstein-Barr virus-related lymphomas. Mediterr J Hematol Infect Dis. 2009;1:e2009010.
39. Shiramizu B,Wilkinson R,Hayashi R. Lymphoproliferative disorders andmalignancies related to immunodeficiencies. In: Pizzo PA, PoplackDG, eds. Principles and Practice of Pediatric Oncology. Sixth Edition 2011. Philadelphia: LippincottWilliams & Wilkins; 683-702.
40. Kuehnle I, HulsMH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95:1502-1505. (Pubitemid 30099868)
41. Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol. 2001;115:112-118. (Pubitemid 32995103)
42. Skoda-Smith S,Douglas VK,Mehta P, et al. Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001;27:329-332. (Pubitemid 32177935)
43. Comoli P, Basso S, Zecca M, et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant. 2007;7:1648-1655. (Pubitemid 46776261)
44. Heslop HE, BrennerMK, Rooney CM.Donor T cells to treat EBV-associated lymphoma.NEnglJMed. 1994;331:679-680. (Pubitemid 24276876)
45. O'Reilly RJ, Small TN, Papadopoulos E, et al. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997;157:195-216. (Pubitemid 27303130)
46. Bondanza A, Valtolina V,Magnani Z, et al. Suicide gene therapy of graft-versus-host disease induced by centralmemory human T lymphocytes. Blood. 2006;107:1828-1836. (Pubitemid 43289360)
47. Bonini C, Bondanza A, Perna SK, et al.The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther. 2007;15:1248-1252. (Pubitemid 46965319)
48. Tey SK, Dotti G, Rooney CM, et al. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:913-924. (Pubitemid 47055386)
49. Heslop HE, Ng CYC, Li C, et al. Long-termrestoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551-555. (Pubitemid 26150682)
50. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bonemarrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBVspecific cytotoxic T cells. Blood. 2000;95:807-814. (Pubitemid 30062700)
51. Comoli P, Basso S, Zecca M, et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant. 2007;7:1648-1655. (Pubitemid 46776261)
52. Melenhorst JJ, Leen AM, Bollard CM, et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010;116:4700-4702.
53. Heslop HE, Slobod KS, Pule MA, et al. Long-termoutcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphproliferative diseases in transplant recipients. Blood. 2010;115:925-935.
54. Moosmann A, Bigalke I, Tischer J, et al. Effective and long-termcontrol of EBV PTLD after transfer of peptide-selected T cells. Blood. 2010;115:2960-2970.
55. Uhlin M, Okas M, Gertow J, et al. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother. 2010;59:473-477.
56. Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006;108:2942-2949.
57. Comoli P, LabirioM,Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder insolid organtransplant recipients with evidence of active virus replication. Blood. 2002;99:2592-2598. (Pubitemid 34525450)
58. Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA. 1999;96:10391-10396. (Pubitemid 29422568)
59. Sherritt MA, Bharadwaj M, Burrows JM, et al. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-termrecovery fromposttransplant lymphoma after adoptive immunotherapy. Transplantation. 2003;75:1556-1560. (Pubitemid 36597295)
60. Brewin J,Mancao C, Straathof K, et al. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood. 2009;114:4792-4803.
61. De Angelis B, Dotti G, Quintarelli C, et al. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009;114:4784-4791.
62. Wilkie GM, Taylor C, Jones MM, et al. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein-Barr virus-associated diseases. J Immunother. 2004;27:309-316. (Pubitemid 38833327)
63. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus- positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet. 2002;360:436-442. (Pubitemid 34880139)
64. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:1123-1131. (Pubitemid 47281407)
65. Gandhi MK, Wilkie GM, Dua U, et al. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant. 2007;7:1293-1299. (Pubitemid 46643124)
66. Barker JN,Doubrovina E, Sauter C, et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood. 2010;116:5045-5049.
67. Leen AM, Bollard CM, Mendizabal AM, et al. Most closely HLA-matched allogeneic virus specific cytotoxic T-lymphocytes (CTL) to treat persistent reactivation or infectionwith adenovirus,CMVand EBV after hemopoietic stem cell transplantation (HSCT). Blood (ASH Annual Meeting Abstracts). 2010;116:829.